This service is more advanced with JavaScript available, learn more at http://activatejavascript.org

Reactions Weekly

July 2016, Volume 1608, Issue 1, pp 8–8 | Cite as

PDE5 inhibitors not associated with malignant melanoma

Clinical study

First Online: 02 July 2016

54 Downloads

This is a preview of subscription content, to check access.

Reference

Matthews A, et al. Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink. PLOS Medicine 13: e1002037, No. 6, 14 Jun 2016. Available from: URL: http://dx.doi.org/10.1371/journal.pmed.1002037 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

About this article

Cite this article as:: Reactions Weekly (2016) 1608: 8. https://doi.org/10.1007/s40278-016-19020-9

DOI https://doi.org/10.1007/s40278-016-19020-9
Publisher Name Springer International Publishing
Print ISSN 0114-9954
Online ISSN 1179-2051

Published in cooperation with
Adis

Personalised recommendations